In this issue:
ABT-530-containing regimen in HCV GT3
Real-world SVR rates with OPrD ± RBV in HCV GT1
Sofosbuvir + daclatasvir: high SVR rates in recurrent HCV infection
Response-guided therapy feasible in chronic HBV
OPrD promising in HCV GT1 and stage 4/5 CKD
Nomogram predicts HCC in HCV-compensated cirrhosis
Improving the care continuum for chronic viral hepatitis
OPrD for HCV GT1b with cirrhosis . . . excellent outcomes in real-life settings
Historical HCV epidemic trends in the US and Australia
Please login below to download this issue (PDF)